Lorenz Kadletz1, Gregor Heiduschka2, Robert Wiebringhaus3, Elisabeth Gurnhofer3, Ulana Kotowski1, Georg Haymerle1, Markus Brunner1, Conor Barry4, Lukas Kenner3,5,6. 1. Department of Otorhinolaryngology, Head and Neck Surgery, Medical University Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria. 2. Department of Otorhinolaryngology, Head and Neck Surgery, Medical University Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria. gregor.heiduschka@meduniwien.ac.at. 3. Department of Pathology, Medical University Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. 4. Department of Oral and Maxillofacial Surgery, National Maxillofacial Unit, St James's Hospital, and Dublin Dental University Hospital, Dublin, Ireland. 5. Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria. 6. Institute of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, Austria.
Abstract
PURPOSE: Previously, the engulfment and cell motility 3 (ELMO3) protein has been reported to be involved in cell migration and cytoskeletal remodeling. As of yet, nothing is known about the role of ELMO3 in head and neck squamous cell carcinoma (HNSCC). The purpose of this study was to asses ELMO3 expression in postoperatively irradiated HNSCC patients and to evaluate a possible correlation between this expression and patient survival. METHODS: 125 postoperatively irradiated HNSCC patients were included in this study. ELMO3 expression was assessed using immunohistochemistry (IHC). The expression of ELMO3 in the respective HNSCC tumor tissues and its lymph node metastases was correlated with patient survival using Kaplan-Meier curve analyses. RESULTS: Through IHC, ELMO3 expression was detected in 71.2% of the HNSCC cases tested. We found significantly increased overall and disease-free survival rates and decreased recurrence rates in patients with no detectable ELMO3 expression. In reverse, we found that ELMO3 expression served as an independent marker for a decreased overall and disease-free survival. CONCLUSION: Our data indicate that in the surgically treated and postoperatively irradiated patients tested, ELMO3 expression serves as a predictive marker for reduced survival.
PURPOSE: Previously, the engulfment and cell motility 3 (ELMO3) protein has been reported to be involved in cell migration and cytoskeletal remodeling. As of yet, nothing is known about the role of ELMO3 in head and neck squamous cell carcinoma (HNSCC). The purpose of this study was to asses ELMO3 expression in postoperatively irradiated HNSCC patients and to evaluate a possible correlation between this expression and patient survival. METHODS: 125 postoperatively irradiated HNSCC patients were included in this study. ELMO3 expression was assessed using immunohistochemistry (IHC). The expression of ELMO3 in the respective HNSCC tumor tissues and its lymph node metastases was correlated with patient survival using Kaplan-Meier curve analyses. RESULTS: Through IHC, ELMO3 expression was detected in 71.2% of the HNSCC cases tested. We found significantly increased overall and disease-free survival rates and decreased recurrence rates in patients with no detectable ELMO3 expression. In reverse, we found that ELMO3 expression served as an independent marker for a decreased overall and disease-free survival. CONCLUSION: Our data indicate that in the surgically treated and postoperatively irradiated patients tested, ELMO3 expression serves as a predictive marker for reduced survival.
Entities:
Keywords:
ELMO3; Head and neck; Postoperative irradiation; Prognosis; Radiotherapy; Squamous cell carcinoma
Authors: Ilda Patrícia Ribeiro; Francisco Caramelo; Francisco Marques; Ana Domingues; Margarida Mesquita; Leonor Barroso; Hugo Prazeres; Maria José Julião; Isabel Poiares Baptista; Artur Ferreira; Joana Barbosa Melo; Isabel Marques Carreira Journal: Cell Oncol (Dordr) Date: 2016-08-04 Impact factor: 6.730
Authors: Elizabeth A Sisk; Scott G Soltys; Shaobo Zhu; Susan G Fisher; Thomas E Carey; Carol R Bradford Journal: Head Neck Date: 2002-09 Impact factor: 3.147
Authors: Signe Søes; Iben Lyster Daugaard; Brita Singers Sørensen; Andreas Carus; Manuel Mattheisen; Jan Alsner; Jens Overgaard; Henrik Hager; Lise Lotte Hansen; Lasse Sommer Kristensen Journal: Oncoscience Date: 2014-05-23
Authors: Giselly Encinas; Veronica Y Sabelnykova; Eduardo Carneiro de Lyra; Maria Lucia Hirata Katayama; Simone Maistro; Pedro Wilson Mompean de Vasconcellos Valle; Gláucia Fernanda de Lima Pereira; Lívia Munhoz Rodrigues; Pedro Adolpho de Menezes Pacheco Serio; Ana Carolina Ribeiro Chaves de Gouvêa; Felipe Correa Geyer; Ricardo Alves Basso; Fátima Solange Pasini; Maria Del Pilar Esteves Diz; Maria Mitzi Brentani; João Carlos Guedes Sampaio Góes; Roger Chammas; Paul C Boutros; Maria Aparecida Azevedo Koike Folgueira Journal: Oncotarget Date: 2018-04-27
Authors: Mike Boger; Katrin Bennewitz; David Philipp Wohlfart; Ingrid Hausser; Carsten Sticht; Gernot Poschet; Jens Kroll Journal: Front Cell Dev Biol Date: 2022-07-08